DVA vs LAB · P/E 14, rev $12.82B vs rev $174.4M
DaVita HealthCare Partners Inc (DVA) versus Standard Biotools Inc (LAB) — a side-by-side from cached financials, not a winner call.
DaVita HealthCare Partners Inc (DVA) is a medical care facilities company listed on US.
Standard Biotools Inc (LAB) is a medical devices company listed on NASDAQ.
Latest reported DVA revenue for 2024-12-31 was $12.82B. Net income was $1.25B. Revenue was up 5.6% from 2023-12-31 to 2024-12-31. DVA currently screens at market cap $10.77B and trailing P/E 14.1.
Latest reported LAB revenue for 2024-12-31 was $174.4M. Net income was -$138.9M. Revenue was up 64.0% from 2023-12-31 to 2024-12-31. LAB currently screens at market cap $317.1M.
DVA currently screens at market cap $10.77B and trailing P/E 14.1. LAB currently screens at market cap $317.1M.
Not investment advice. Open the DVA and LAB stock pages for the full models.
Not investment advice.